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Key points 
 
The management of infection in Intensive Care Unit  represents an imperative challenge for 
critical care clinicians. At present, antibiotic dosing regimens are derived from studies on 
healthy volunteers and do not account for these major differences in drug make up.  
 Critical illness is characterised by marked homeostatic disturbance, altered end-organ 
function, variable pre-existing comorbidity, and anthropometric irregularity. Such changes 
significantly distort the normal drugs PK profile, resulting in drug exposure that is markedly 
different from the “healthy volunteer” 
 Renal Clearance is often modified in critical illness due to either acute kidney Injury or, on 
the other hand, to augmented renal clearance.  
 CRRT have a profound effect on pharmacodynamics parameters of the antimicrobial agents 
 Based on understanding of the principles drug removal by continuous renal replacement 
therapy, individual antimicrobial dosage and dosing interval may be estimated by 
mathematical equation 
 
 
 
 
 
 
 
 
 
  
Abstract 
 
The management of infection in Intensive Care Unit represents an imperative challenge for critical 
care clinicians. At present, antibiotic dosing regimens are derived from studies on healthy 
volunteers and do not account for these major differences in drug prescriptions. We summarized the 
pharmacokinetic/pharmacodynamics relationship changes in antimicrobial agents due to the typical 
homeostatic disturbance or altered end-organ function of the critical illness. We focused on how the 
renal clearance alterations or the Continuous Renal Replacement Therapy may affect individual 
antimicrobial dosage and dosing interval of the antimicrobial agents.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 176 
 
 
1. BASIC PHARMACOLOGICAL PARAMETERS OF ANTIMICROBIAL AGENTS 
The therapeutic effects of antibiotics depends on   the achievement and maintenance of an 
adequate therapeutic free concentration at the site of infection.  The concentration at the site of 
action is the result of several complex processes occurring in the body after drug administration          
Pharmacokinetics (PK) studies the evolution of the concentration of the admistered drug in the 
different compartments of the patient body over the time. After the administration, the plasma levels 
a given drug undergoes modification over time due to several of processes: absorption, distribution, 
metabolism and excretion (ADME)1. These changes represent the time-profile concentration, which 
is characterized by PK parameters, such a total body clearance (CL), Volume of distribution (Vd), 
plasma protein binding (PPB) and bioavailability (BA)1. Finally, in the site of the action at the 
required concentration, a drug produces the expected effect thanks of its mechanism of action. The 
Pharmacodynamics (PD) studies the biochemical and physiological effects of drugs and their 
mechanisms of action. Pharmacodynamics parameters relate the pharmacokinetic factors to the 
ability of an antimicrobial to kill or inhibit the growth of the pathogen organism antibiotics, and 
different antibiotic classes have different kill characteristics on bacteria. For this reason, the 
knowledge of the pharmacokinetic and pharmacodynamic properties of the antibiotics is essential 
for selecting the optimal dosage regimen. In the treatment of critically ill patients, the determination 
of individualized dosing regimens becomes even more difficult as a consequence of 
pathophysiological changes, organ failure and the need for organ-supportive therapy. 
The pharmacokinetic changes induced by organ failure and critical illness must be considered and 
are particularly important for drugs with a small volume of distribution or high protein binding or 
both. 
1.1. Pharmacokinetic parameters 
 Usually, in critically ill patients antimicrobial agents   are administered  by the intravenous (IV) 
route. Enteral administration (PO) route is not the first choice considering the altered adsorption 
processes due to oedema or inflammatory status of gastrointestinal mucosae. 
 The main pharmacokinetic parameters are the following: 
 Bioavailability (BA), relating to antibiotics administered by an extravascular route (i.e. oral 
route) 
 Plasma protein binding (PPB) 
 Maximum (peak) plasma drug concentration achieved by a single dose (Cmax) 
 Minimum plasma drug concentration during a dosing period (Cmin) 
 
 Area under the plasma concentration-time curve (AUC) 
 Volume of distribution (Vd) 
 Clearance (CL) 
 Half-life (T1/2) 
 
Bioavailability  
Bioavailability refers to the degree that a drug is absorbed into the systemic circulation after 
extravascular administration: when the drug is administered by the IV route, 100% of the dose is 
bioavailable, whereas a drug administered by the PO route has to cross further barriers (absorption 
by gastric or intestinal mucosa, metabolism in liver also know first passage effect) to reach the 
systemic circulation, which can significantly reduce the final extent of a drug in the bloodstream.  
In renal failure, numerous pathological factors and the clinical use of antacids, or alkalinizing 
agents may decrease gastrointestinal absorption. First-pass hepatic metabolism may also be 
diminished in uraemia, leading to increased serum levels of oral antibacterial agents2. 
 
Plasma protein binding 
Plasma protein binding influences the Vd, the CL and the drug clearance during Renal Replacement 
Therapy (RRT) of many antibiotics. Exclusively, the plasma free (unbound) moiety of drugs is able 
to diffuse in the body and to be cleared off from plasma by kidney, liver or extracorporeal 
clearance.  
Plasma drug concentration (Cmax, Cmin, AUC) 
After PO, at the time when the rate of the drug entering the plasma (absorption) and the rate of the 
drug disappearing from the plasma (distribution and elimination) are equal, or at completion of IV 
infusion, the maximal concentration (Cmax) is reached. Thereafter, the rate of distribution or 
elimination of the drug exceeds the rate of drug absorption, and the plasma concentration starts to 
decline to a minimal concentration (Cmin). The Area Under the plasma concentration-time Curve 
(AUC) is a pharmacokinetic measure that indicates the exposure to a drug during the full dosing 
interval (Figure 1).  
When starting an antibiotic drug therapy, the loading dose (LD) is administered in order to rapidly 
achieving therapeutically effective concentrations, whereas the maintenance doses (MD) are 
administered in order to maintain the effective levels over time by replacing the amount eliminated 
from the body during the dosing interval. Plasma levels for a given drug (Cmax, Cmin) are a function 
of the dose, bioavailability, volume of distribution, and rate of metabolism and excretion. Therefore, 
PK changes   affect the antibiotic concentration at the target site and, finally, the clinical outcome. 
Volume of distribution 
Distribution is the process by which a drug diffuses from the intravascular to extravascular 
compartments, and it is described by the drug's Vd, that represents the volume of body fluid into 
which a drug's dose is dissolved. The Vd is important in calculating the plasma half-life (T1/2) of a 
drug, and may also be used to determine the loading dose. The presence of ascites or oedema may 
necessitate a larger dose, whereas dehydration may require a reduction in the dose. 
The Vd is calculated by dividing the amount of drug in the body by the plasma concentration. 
Usually, highly protein-bound or hydrophilic drugs are found mainly in the vascular compartment 
and have a small Vd, whereas poorly PPB or lipophilic drugs have a large Vd because they are able 
to penetrate body tissues.  
A Vd of about 0.06 L/kg of body weight corresponds to the plasma compartment, a Vd of about 0.2 
L/kg corresponds to the extracellular fluid compartment, and a Vd of about 0.4 L/kg corresponds to 
the intracellular fluid compartment. If the Vd exceeds the total body water (>0.6 L/kg), the drug is 
likely sequestered in the intracellular fluid of certain tissues3. 
Clearance 
Drug clearance from the body is the result of elimination by renal excretion and by extra renal 
pathways (no renal clearance), usually by liver metabolism. The unbound moiety of the drug can be 
eliminated, so an increasing in the plasma level of free drug, commonly observed in critically ill 
patients, may significantly reduce the clearance mainly for highly protein-bound antibiotics, such as 
ceftriaxone.  
In patients treated with extracorporeal treatment (e.g. RRT), total clearance is the sum of 
extracorporeal clearance, no renal clearance and residual renal clearance, and this situation further 
complicate calculations of dose modification.  
Half-life  
It is common that the rate of plasma clearance is expressed as the time required for the plasma 
concentration of a drug to decline by 50%, that is the T1/2. After rapid IV administration, the decline 
in plasma drug levels may follow a biphasic curve. The T1/2 of the initial phase (alpha-phase T1/2) 
represents distribution of the drug, and the T1/2 of the second phase (beta-phase T1/2) represents 
elimination of the drug from the body. The T1/2 that is usually reported is the beta-phase T1/2. The 
T1/2 remains constant at all times for all drugs that follow first-order kinetics because  of 
concentration decreased, so does the rate of plasma clearance. Drug elimination T1/2 is directly 
related to CL and Vd. It follows that an increased drug CL is likely to reduce T1/2, whereas an 
increased Vd is likely to increase T1/2. 
 T1/2 is the pharmacokinetic parameter most changed with renal dysfunction in particular for 
hydrophilic antibiotics (Figure 2). 
 
1.2. Antibiotics classification based on physico-chemical properties 
Although there are several classification schemes for antibiotics based on bacterial spectrum (broad 
versus narrow), route of administration (injectable versus oral versus topical), type of activity 
(bactericidal versus bacteriostatic), or chemical structure, the classification based on their physico-
chemical properties is useful in order to predict the dosage adjustment in critically ill patients. The 
pharmacokinetics of drugs is influenced either by the physico-chemical properties of the molecule, 
either by the clinical conditions of the patient, that can alter the normal ADME processes. 
Furthermore, most sites of infection are extravascular, and their treatment depends on diffusion of 
the antimicrobial agent out of the bloodstream and into interstitial and intracellular fluid. The ability 
of a drug to reach the site of infection depends on tissue-related factors (i.e. perfusion to the tissues, 
surface area of the tissue's vascular bed, existence of tight junctions or capillary pores) and drug-
related factors (such as lipid solubility, molecular size, the drug's pKa, and PPB). An important 
drug-related factor is the hydrophilicity-lipofilicity balance of the molecule, which is usually 
expressed by the logP. The logP value of a compound is the 10-base logarithm of the concentration 
ratios between non-aqueous (octanol) and aqueous (water) phase (logPO/W). 
Antibiotics can be classified as hydrophilic or lipophilic (hydrophobic) compounds, according to 
their logP; hydrophilic antibiotics are characterized by low logP values, whereas lipophilic 
antibiotics are typified by higher values (Figure 2). Hydrophilic antibiotics (e.g. Aminoglycosides, 
Carbapenems, Cephalosporins, Glycopeptides, Penicillins) are characterized by a lower volume of 
distribution, are unable to cross the plasmatic membrane (with the consequence of inefficacy 
against intracellular bacteria), and are eliminated mainly by kidneys as unchanged parent drug. 
Administration of hydrophilic antibiotics in patients affected by impaired renal function requires 
usually a modification of the dosage regimen in order to avoid toxicity caused by the accumulation 
of the parent drug or its metabolites.  
Lipophilic antibiotics (i.e. Fluoroquinolones, Macrolides, Tetracyclines, Chloramphenicol) are 
characterized by a higher volume of distribution, are able to cross the plasma membrane (they are 
active against intracellular bacteria), and are eliminated mainly after liver metabolism. 
Physico-chemical properties of antibiotics affect also their clearance during RRT as a consequence 
of their different distribution in the body, according to the theory that the larger the Vd, the less 
likely it is that the drug will be removed by RRT.  
Hydrophilic compounds, because of their distribution limited to the plasma and to the extracellular 
space, are promptly and efficiently removed by RRT, so the amount of cleared drug should be 
carefully evaluated in order to adjust the dosage regimen (during and after the RRT).  Conversely 
lipophilic compounds are able to cross the plasmatic membrane and accumulate in the intracellular 
compartment, so only a small fraction of the total drug amount present in the body can be removed, 
even with a 100% extraction across the RRT filter, so supplemental dosing (during or after RRT) is 
usually not necessary4. 
The effect of molecular weight (MW) on drug dialyzability is dependent on the type of dialytic 
membrane and extracorporeal technique. Drug removal is expected to be dependent on MW only if 
the filter membrane cut-off is lower than the size of the considered drug. This aspect is completely 
irrelevant for hemofiltration techniques, because almost all antibiotics have MW less than 2000 Da, 
a value significantly lower than the hemofilter cut-offs, (about 30,000 to 50,000 Da)5.  
 
1.3. Pharmacokinetic/Pharmacodynamics relationship 
Pharmacodynamics (PD) is the study of the biochemical and physiological effects of drugs and their 
mechanisms of action (Table 1).  
The major indicator of the effect of the antibiotics is the minimum inhibitory concentration (MIC) 
that provides information on the susceptibility of the pathogen against the antibiotic. MIC is 
estimated by different methodologies in the laboratory, and it is defined as the minimum 
concentration of the antibiotic able to inhibit the growth of the pathogen organism. The use of the 
MIC as the only marker of the efficacy of antimicrobial therapy has many limits, as the therapeutic 
goal depends on the interactions between drug concentration at the site of infection, bacterial load, 
phase of bacterial growth, and the MIC for the pathogen. It follows that a change in any of these 
factors will alter the activity of the antimicrobial agent against the pathogen and may affect the 
pharmacological outcome. 
Pharmacokinetic/Pharmacodynamics (PK/PD) analysis integrates all this information allowing the 
clinician to select the optimal antibiotic and dosing regimen for each infectious process and patient, 
in order to enhance the effect of the antibiotic, minimizing the side effect incidence and the 
emergence of resistance6.  
The primary PK/PD indices are the following (Figure 1): 
 Duration of time the plasma concentration of a drug remains above the MIC for a dosing 
period (T>MIC)  
 Ratio of the Cmax to MIC (Cmax/MIC) 
 Ratio of the AUC during a 24-hour period to MIC (AUC/MIC) 
 Post antibiotic effect (PAE), defined as persistent suppression of bacterial growth after a 
brief exposure of bacteria to an antibacterial agent, even in the absence of host defences.  
 
1.4. PK/PD classification of antibiotics 
Regarding to PK/PD relationship, antimicrobials can be categorized by their pathogenic kill 
characteristics. Understanding these characteristics can aid the clinician in formulating an optimal 
antimicrobial treatment regimen for an individual patient.  
Three major patterns of antimicrobial activity have been described (Figure 1)7,8: 
 Antibiotics with time-dependent killing. The best PK/PD index correlated with efficacy is 
T>MIC. These drugs have relatively slow bactericidal action and no or short PAEs. This 
pattern has been described for all of the β-lactam antibiotics, such as penicillins, 
cephalosporins, and carbapenems. 
 Antibiotics with concentration-dependent killing. The best PK/PD index correlated with 
efficacy is Cmax/MIC. These drugs achieve increasing bacterial kill with increasing levels of 
drug. In addition, these agents have an associated concentration-dependent PAE in which 
bactericidal action continues for a period of time after the antibiotic level falls below the 
MIC. This pattern has been observed with a large number of antimicrobials including some 
aminoglycosides and fluoroquinolones, daptomycin and metronidazole. 
 Antibiotics with concentration-dependent with time-dependence killing. The best PK/PD 
index correlated with efficacy is AUC/MIC. These drugs are predominantly bacteriostatic 
and produce moderate to prolonged PAEs. This pattern is characteristic of tetracyclines, 
tigecycline, oxazolidinones, and some aminoglycosides and fluoroquinolones. 
 
 
2. ANTIBIOTICS IN CRITICAL ILLNESS 
 
2.1. Rationale for personalised dosage adjustment in critically ill patients 
The management of infection in ICU represents an imperative challenge for critical care clinicians. 
Useful therapy is based on early recognition of infection and the timely administration of an 
antimicrobial therapy to combat the contributing pathogens. Moreover, the mortality in this setting 
remains high, and simultaneous resistance to antibiotics abruptly increases. 
At present, antibiotic dosing regimens are derived from studies on healthy volunteers and do not 
account for these major differences in drug make up. This present approach is likely to lead to 
suboptimal outcomes for critically ill patients9.  
On the other hand, the critically ill represent a unique population. Critical illness does not have 
“linear dynamics”10 of beginning and development: it is characterised by marked homeostatic 
disturbance, altered end-organ function, variable pre-existing comorbidity, and anthropometric 
irregularity. Such changes significantly distort the normal drugs PK profile, resulting in drug 
exposure that is markedly different from the “healthy volunteer”11.  
Furthermore, critically ill patients are treated with combination therapy that can affect the PD/PK 
antibiotic characteristics. Sometimes they undergo treatments that intuitively could influence the 
drugs plasma levels (e.g. ECMO or RRT), but very little data is available for this. 
Nowadays, the microbial epidemiology of ICU shows an increased prevalence of multidrug 
resistance (MDR) bacteria, mandating the application of higher antibiotic concentrations for killing 
bacteria successfully.  
Antimicrobial stewardship programs (ASPs) are multidisciplinary programs whose primary aim is 
to optimize antibiotic use (improve clinical outcomes; minimize the untoward effects of 
antimicrobial use, and selection of resistant pathogens) in order to reduce ICU length of stay and 
costs. ASPs usually include several strategies: educational programs, implementation of guidelines, 
and prospective audit. Interestingly, it also decreases consumption of non-restricted antibiotics. 
Understanding of the PK/PD changes of antibiotics during CRRT is a relevant part of ASPs12. 
 
2.2. Impact of critical illness on the pharmacological of antimicrobial agents 
Most causes of admission to an ICU (polytrauma, septic shock, severe acute pancreatitis, major 
surgery) trigger an uncontrolled mediator’s cascade leading to pathophysiological changes in 
haemodynamics, tissue perfusion, and immuno-system competence.  In this context, one or more 
organ failures could occur. These pathophysiological changes are relevant in altering the intra and 
extra-cellular volume, the synthesis and the plasma levels of the protein or the clearance ability of 
the organs. Futhermore, they affect the distribution volume (Vd) and the protein binding (PPB) of 
the clearances (CL) of antimicrobials. The entity of the pharmacokinetic alterations depends on 
physic-chemical characteristics of antibiotics. 
Vd significantly increases in critically ill patients due to expansion from rigorous fluid resuscitation 
and increased vascular permeability, leading to trans-capillary leakage of fluid and proteins into the 
extracellular compartment. Vd is also affected by hypoalbuminemia that can have a profound effect 
on highly albumin bound antimicrobials13.  Hypoalbuminemia < 25 g/dl is only likely to influence 
antibiotic PK when the agent is highly protein-bound (>90%)14 and mainly eliminated by kidneys 
(e.g. ceftriaxone, teicoplanin and ertapenem)13. 
As a consequence, the significant expansion of the extracellular fluid may lead to a consistent 
increase in the Vd of drugs
15. However, the importance of this extra-volume in affecting drug Vd is 
different between hydrophilic and lipophilic antimicrobial agents15. 
Hydrophilic compounds (beta-lactams, glycopeptides, lipopeptides, aminoglycosides, azoles as 
fluconazole or ecchinocandins) are distributed primarily in extracellular space. As such, they 
present an increased Vd, so that a huge dilution is expected
15. 
Conversely, no relevant increase of Vd is expected for lipophilic drugs. In effect, the considerable 
drug accumulation within the cells, by acting as drugs reservoir, is compensated by passive 
diffusion for any dilution for lipophilic drugs that can occur in the extra-cellular space15. For 
intravenously administered drugs, the Vd determines the dose (D) needed to achieve the desired 
plasma concentration (C), in a patient with ideal body weight (IBW): 
D = C x Vd x IBW [1]11 
The IBW in kilograms can be calculated from the height (H) in inches or centimeters, as follows: 
IBW male = 50 + 2.3(Hinches - 60) = 0.9(Hcm) – 88 [2]2,3 
IBW female = 45.5 + 2.3(Hinches - 60) = 0.9(Hcm) – 97 [3]2,3 
For each kilogram of oedema, ascites, or effusion fluid, an additional drug dose may be added to the 
usual dose (e.g. for aminoglycoside an additional 20 mg may be added to the usual dose). 
For antibiotic dosing in the morbidly obese, a similar strategy applies: the dosing weight is the IBW 
plus 0.4 x (Total body weight - IBW)16.  
In critically ill patients the actual Vd may differ from values obtained from pharmacological tables, 
and it shows great inter and intra-individual variations. This may increase the error when using Vd 
in estimating drug dosing. The Vd of aminoglycosides increases approximately 25% in the critically 
ill, whereas vancomycin, metronidazole, and most beta-lactam antibiotics show near normal values, 
but with individual variations. 
As previously mentioned, critically ill patients have low protein plasma levels. The unbound 
fraction of the drugs (fu) is responsible for the efficacy and toxicity of the molecule14,17. Fu is the 
fractions readily available for the clearance by the organ (kidney, liver, and bowel) elimination 
pathway. Obviously, an increased fu results in a larger Vd and a faster renal clearance
14. On the 
other hand, critically ill patients often have increased levels of acid α1-glycoprotein11, which may 
increase protein binding of some drugs. Thus, the reported unbound fraction in healthy volunteers 
and in patients with chronic renal insufficiency may differ substantially from the unbound fraction 
of drugs in critically ill patients. The part of drugs bound to the acid-α1-glycoprotein remains 
unknown and no data is available in current literature. 
 Sometimes in critically ill patients, a hyperdynamic state causes an increase in renal (Augmented 
Renal Clearance, ARC)14,18,19 or liver (Augmented Liver Clearance, ALC) elimination pathway of 
the molecules. The ARC is probably caused to increased blood flow, with consequent in Glomerular 
Filtration Rate20,21. The ARC occurrence rate was determined around 15-20% among critically ill 
patients, even if in subpopulation of this patients it seem to be higher22.  
A clinically useful measure of ARC is a timed urinary creatinine clearance (CLCr). Use of this 
surrogate is reinforced by observed association between elevated measures (≥ 130 ml/min/1.73 m2) 
and suboptimal antibiotic concentration for renally eliminated agents19,23. 
ARC has been identified in critically ill patients of a younger age, lower scores of illness severity, 
and with clinical conditions where an increased cardiac index (CI) has been observed (pregnancy, 
anaemia, “hyperdynamic phase” of septic shock)19.  
On the other hand, plasma creatinine-based equations such as the Cockcroft-Gault, Modification of 
Diet in Renal Disease (MDRD) and chronic kidney disease revealed limited accuracy, particularly 
in patients manifesting ARC23. 
In the setting of the antimicrobial dosing regimens, the physiochemical aspects of the drugs and the 
pathological changes of the critical illness affect the types of administration. 
As previously mentioned, the LD is the quantity of drugs employed to ensure the quick and efficient 
achievement of the therapeutic concentration target (TCT). 
This is the product of the effective plasma concentration and the apparent Vd. After a single 
intravenous bolus, the concentration plasma levels decrease over time as a consequence of drug 
distributions. Consequently, in a critically ill setting, where there is a larger Vd than in healthy 
volunteers, a standard dose results in the failure of the achievement of TCT. 
The LD of a given drug is influenced only by its Vd and not by its CL because the LD depends 
exclusively on the body’s compartments where it is spread out, and not on the capacity of 
elimination of each organ, like the kidneys and the liver.  In agreement with this concept, the LD for 
a given drug has to be calculated irrespective of renal and/or hepatic function15,24.  
Consequently, the LD should be increased for hydrophilic antimicrobials where the clinical 
conditions caused a more expanded Vd, in order to achieve the TCT. For example, the extracellular 
fluid is the Vd of aminoglycosides and includes oedema, ascites, and effusion fluids. A standard per-
kilogram LD would be inadequate in patients with these conditions, so the amount of excess 
extracellular fluid should be estimated and the dose increased accordingly. Alternatively, 
extracellular volume depletion reduces the aminoglycoside Vd
15, and a standard per-kilogram LD 
would be excessive. This may explain the increased incidence of aminoglycoside nephrotoxicity in 
obese patients, who have a reduced fraction of total body weight that is extracellular water3. In 
addition to the nature of the infection (site, medical versus surgical therapy, life-threatening versus 
less serious), the suspected organism and its MIC should be considered. For example, Pseudomonas 
Aeruginosa has an MIC for gentamicin or tobramycin that is usually less than 2 mg/L. If a ratio of 
10 times the MIC is desired for efficient Pseudomonas a. killing, a peak concentration of 10 to 20 
mg/L will be required. 
On the other hand, in critically ill patients the lipophilic antimicrobials do not have a relevant 
enlargement of Vd, because, as previously mentioned, the extent of drug accumulation within cells, 
may promptly compensate the passive diffusion due to any dilution of lipophilic antibiotics. This is 
especially true for those antibiotics which present the largest intrinsic Vd, like tigecycline. 
Accordingly, there is no rationale for increasing the LD of lipophilic antimicrobials in critically ill 
patients15.  
The right LD permits adequate plasma concentration in a short time. The MD must be calculated in 
order to maintain the optimal patient exposure over time. In contrast with LD, the DMD is mainly 
dependent on the drug CL. Whenever the elimination pathway of a given drug is altered in critically 
ill patients, the MDs become significantly different from the standard ones15.  In this setting, a 
continuous evaluation of the elimination pathways from the organs is mandatory to avoid a failure 
of the TCT achievement or the toxicity of the drug. The daily assessment of organ functions is 
necessary in order to prevent an eventual alteration in drug clearance. 
The Therapeutic Drug Monitoring (TDM) would be the best tool to target the right LD and MD in 
critical illness. Nevertheless, this method often has a narrow spectrum of utilisation, in order to 
prevent the toxicity of some nephrotoxic antibiotics. TDM is used worldwide with aminoglycosides 
and glycopeptides to ensure appropriate exposure and minimize the incidence of toxicity, whereas 
TDM use is unusual in targeting the right dose for the other antibiotic classes, even though recent 
studies have assessed its usefulness in critically ill patients19. 
For “empirical” dosing, that is in absence of TDM, the PK/PD models are imperative for each 
antimicrobial agents19,25. 
 
3. IMPACT OF ACUTE KIDNEY INJURY ON PHARMACOLOGICAL 
CHARACTERISTICS OF ANTIMICROBIAL AGENTS 
 
3.1. AKI without CRRT: drug dosing adjustment 
Total body clearance of an antimicrobial agent is the sum of clearances from different sites in the 
body, which may include hepatic, renal, and other metabolic pathways. In general, hydrophilic 
agents are cleaned by the kidney and lipophilic drugs are not renally cleared. Some notable 
exceptions to this general rule may exist. Ceftriaxone and oxacillin, although hydrolifilic molecules, 
are cleaned by biliary elimination. Opposite, levofloxacin and ciprofloxacin, although lipophilic, are 
renally cleared26. 
The amount of renal clearance on the total body clearance is the major factor in the dosing 
adjustments in renal failure. If the renal clearance of a drug is normally less than 25–30% of total 
body clearance, impaired renal function is unlikely to have a clinically significant influence on drug 
removal11.  
The most universal pharmacokinetic equation is : 
T1/2 = 0.693 x Vd/CL [4]2 
Because T1/2 is reciprocal to the clearance, an interpolation for any degree of renal impairment can 
be made from the extreme values for normal kidney function and anuria.  
Neither renal failure nor extracorporeal blood purification (ECBP) therapy requires adjustment of 
the LD, which depends solely on Vd. Maintenance doses for drugs that undergo considerable renal 
excretion should be adapted to the reduced renal clearance, however. Two different approaches are 
used in adjusting drug dosage in accordance with degree of impairment of renal function in patients 
that do not do dialysis: the Dettli’s rule and the Kunin’s rule. 27,28 Dettli's proportional dose 
reduction rule adjusts the maintenance dosage in proportion to the reduced clearance. Alternatively, 
Kunin's half-dosage rule is derived from the elimination T1/2. The normal starting dose is given, and 
one half of the starting dose is repeated at an interval corresponding to one T1/2. The Dettli’s rule 
results in an AUC that is the same as in normal subjects. With the Kunin’s rule, the peak levels 
(Cmax) are identical, but the AUC and the Cmin are higher than in normal subjects
28. 
 Hydrophilic antimicrobials are mostly renally cleared by glomerular filtration and tubular 
secretion29. Decreased clearance of these drugs is well described in renal dysfunction, and as dose 
reductions (in time-dependent antimicrobials) or extended dosing intervals (in concentration 
dependent antimicrobials) are required to prevent drug accumulation and toxicity29. 
Early diagnosis of AKI and assessment of renal function are mandatory for daily dose adjustment of 
hydrophilic antibiotics. This task is not easy: the creatinine clearance in patients with highly 
reduced renal function overestimates the glomerular filtration rate (GFR) because of the increased 
contribution of tubular excretion. The estimations of creatinine clearance (CrCL) as a surrogate 
GFR using formulas such as Cockroft-Gault and Modified Diet in Renal Disease (MDRD) are 
widely utilised, but results must be interpreted carefully in critically ill patients29. In effect, its 
application in critical illness has been questioned, because MDRD has not been validated yet in this 
setting29. In critical illness plasma creatinine concentrations can be altered for several reasons, from 
the worsening of renal function to a persistent catabolic state. In this context, these formulas may 
result to an inexact estimation of GFR and consequently may conduct to inappropriate dose 
adjustments. Therefore, in critically ill patients it would be preferable to calculate urinary CrCL at 
least once daily in order to estimate GFR18.  
Moreover, some antibiotics, such as aminoglycosides, have a narrow therapeutic window. In this 
case, dose adjustments are imperative to prevent toxicity that can produce additional nephrotoxicity, 
and may cause a greater antibiotic accumulation.  A vicious circle of injury may start in the already 
damaged kidney.  
Antibacterial and antifungal drugs possess an intrinsic nephrotoxic potential, which is mostly dose 
dependent for drugs inducing crystal formation and for drugs that act directly on tubular cells or on 
intra-renal hemodynamic. Prolonged duration of treatment increases the nephrotoxicity of 
aminoglycosides and amphotericin. Once-daily dosing is effective and actually less toxic than 
multiple daily doses, because several drugs have a proximal tubule saturable uptake. The rate of 
administration is important for drugs that cause crystal-induced nephropathy. Amphotericin infu-
sion over 45 minutes did not induce more nephrotoxicity than an infusion over 4 hours, and a 
continuous infusion appeared to be safer than a 4-hour infusion. The nephrotoxicity of amphotericin 
B is related to renal vasoconstriction and direct tubular damage by deoxycholate, which is used as a 
solubilizing agent. Specific drug combinations may result in synergistic nephrotoxicity, such as 
certain cephalosporins and aminoglycosides, the combination of vancomycin and amino-glycosides, 
or the combination of cephalosporin and acyclovir. 
 When the dose reduction due to impaired renal function is mandatory, it is essential to consider 
antibiotic pharmacodynamics to ensure that targets are still attained by avoiding the toxicity. For 
instance, for time-dependent antibiotics, an appropriate strategy should be the dose reduction rather 
than to modify the frequency of administration in order to preserve the T/ MIC29. For concentration-
dependent drugs, a right LD permit to reach the peak concentration required for optimum bacterial 
killing. In this setting, the better strategy is to prolong the interval between the doses29.  
However, despite these theoretical recommendations, uncertainty is always present when 
prescribing antibiotics in patients with  multiple organ dysfunction syndrome (MODS) because 
organ function is very likely to fluctuate. It follows that TDM is again a useful tool to titrate 
antibiotic dosing in MODS.  
Effectively, The Surving Sepsis Campaign Guidelines recommended that the MD of renally cleared 
antimicrobials are reassessed daily in critically ill patients in order to improve efficacy and /or to 
avoid toxicity risk30. Considering that hydrophilic drugs are usually excreted unchanged by the 
kidney, whereas the lipophilic ones are usually bio transformed by the liver, to specify the right 
MD, similar to what happens for the LD in critically ill patients, it is more relevant for hydrophilic 
antimicrobials than for the lipophilic ones15. 
Drug dosing adjustments can be performed by reducing the dose according total clearance decrease. 
For the anuric patient this makes: 
D=DN x CLANUR/CLN [5]11 
Where DN is the normal dose, CLANUR is drug clearance in anuric patients, and CLN is normal drug 
clearance. CLANUR and CLN are retrieved from pharmacological tables. 
On the other hand, published tables or software exist where the empirical doses are listed on the 
basis of CLCr31 (Tables 2 and 3). 
In many clinical settings, the need for a potentially nephrotoxic treatment outweighs the risk of 
causing kidney dysfunction. In these situations, measures are required to prevent or at least 
minimize drug-induced renal damage. General preventive measures for nephrotoxicity include 
addressing all the previously mentioned risk factors that can be corrected or modified. Besides 
correct dosing and reassessment of concomitant medications, ensuring adequate hydration is of 
utmost importance before the administration of nephrotoxic drugs32. The evidence for preventive 
hydration is mostly from observational studies, but it is questionable whether more rigorous studies 
will ever be conducted. The importance of hydration has been shown for amphotericin, and for 
drugs that cause crystal-induced nephropathy. Sodium administration is useful to prevent 
amphotericin B nephrotoxicity33. Intervention on urinary pH with urinary alkalinisation may reduce 
crystal precipitation of some drugs such as sulfadiazine, whereas acidification reduces indinavir 
precipitation34. 
 
3.2. AKI needing CRRT 
When kidney clearance is the predominant elimination pathway of the given drug, RRT/CRRT 
causes a substantial removal of the drug and dosing adjustments are frequently required. 
 Obviously, if its renal clearance is less than 20%11,26, CRRT will have little influence on total body 
clearance and dosing adjustments do not have to be considered. Nevertheless, during hepatic failure, 
the extent to which CRRT contributes to total body clearance may increase, and dose adjustments 
may become necessary.  
As happens in kidney clearance, there are other drug properties affecting clearance by CRRT: Vd, 
PPB and the resulting fu, MW, and drug charge. Only the unbound fraction of a drug is available for 
filtration, and drugs with a high protein binding are poorly cleared by CRRT. Many factors may 
alter the fraction of unbound drug such as systemic pH, heparin therapy, hyperbilirubinemia, plasma 
concentration of free fatty acids, relative concentration of drug and protein, as well as the presence 
of uremic products and other drugs that may act as competitive displacers11.  
Drug charge affects clearance by the Gibbs-Donnan effect. The Gibbs-Donnan effect may have a 
significant effect on polycationic drugs11,35. Because large anionic molecules such as albumin do 
not pass through membranes readily, and retained proteins on the blood side of the membrane make 
the membrane negatively charged, they may partially retard the transmembrane movement of 
polycationic drugs (e.g., aminoglycosides). This drug charge and membrane interaction may explain 
in part the discrepancy between plasma protein binding and observed sieving coefficient (SC). 
A large Vd reflects a drug that is highly tissue bound, and consequently only a small proportion 
actually resides in the vascular compartment available for clearance by endogenous or extra-
corporeal routes.  
The larger the Vd is, the less the drug will be removed by RRT. A drug with a small Vd (≤ 1LxKg-1) 
is more likely to be cleared by extracorporeal therapies than a drug with a large Vd (≥2 LxKg-1). 
However, there is a significant difference between IHD and CRRT35,36. A drug with a large Vd and 
high clearance during high-flux IHD will rapidly be removed from plasma, but only a small amount 
of the body’s drug content is removed during one dialysis session, and plasma concentration will be 
restored between therapies. CRRT by its continuous and slower action has much less influence on 
plasma concentrations of drugs with large Vd, because there is time for continuous redistribution of 
the drug from the tissues to the blood. Although drug elimination during CRRT is much slower for 
drugs with large Vd than for drugs with small ones, the same is true for endogenous (hepatic) 
elimination which has to clear the same Vd. As a consequence, drug dosing adjustments to be made 
during CRRT are much more dependent on the relative contribution of CRRT to total body 
clearance of the drug than on the drug’s Vd5. 
Most drugs have a MW ≤ 500 Da, and very few are greater than 1500 Da (vancomycin at 1448 Da). 
Conventional dialysis membranes favour diffusive clearance of low molecular weight solutes below 
500 Da, whereas the typical high-flux membranes used for CRRT have larger pores (20 000– 30 
000 Da), making no significant filtration barrier to unbound drugs5,11. 
As mentioned previously, the total body clearance of an antimicrobial agent is the sum of clearances 
from different sites in the body and in case of patients needing CRRT, the amount of clearance of 
the extracorporeal therapy should be taken into account37,38. ECBP elimination, measured as frac-
tional extracorporeal clearance (FrEC), is considered clinically significant if its contribution to total 
body clearance exceeds 25% to 30%, is:  
 FrEC = CLEC/(CLEC + CLnr + CLr) [6]37,38   
Where CLEC is extracorporeal drug clearance, CLnr is non-renal drug clearance, and CLr is renal 
drug clearance. This also explains why ECBP elimination will not be clinically relevant for drugs 
with predominantly non-renal clearance. Although it often is difficult to estimate residual renal 
function (RRF) in ARF, such remaining function also needs to be taken into account in determining 
total body clearance. Moreover, significant RRF reduces the fraction that is removed by ECBP 
procedures, which may render ECBP elimination negligible. 
Of note, ECBP elimination replaces only glomerular filtration. By contrast, CLr includes 
glomerular filtration, tubular secretion, and reabsorption. Therefore, any attempt to determine the 
extracorporeal creatinine clearance using the same dosage guidelines as in patients with reduced 
renal function cannot be recommended, especially with drugs largely eliminated by tubular 
secretion. 
As a general rule, the efficacy of the drug removal by different techniques is expected to be 
CVVHDF > CVVH >IHD26, but indeed CLCRRT may vary greatly, because it depends on the 
physico-chemical characteristics and the PK behaviour of each single compound. 
Drugs significantly cleaned during CVVH or CVVHDF, need to increase the dose regimen in 
comparison with renal failure or even IHD. The approach taken depends on the type of 
antimicrobial activity (time or concentration dependent antimicrobial).  
For time-dependent antimicrobials the time during which concentrations are maintained above the 
MIC of the etiological agent (T>MIC) is the most relevant PD parameter. In this regard, it is 
necessary to ensure that the Cmin is four or five times that of the MIC. According to this issue, the 
best approach is to maintain the frequency of drug administration, modifying the amount of each 
single dose. 
Conversely, for concentration-dependent antimicrobials the most important PD parameter is the 
ratio between the Cmax and the MIC, with excellent exposure when Cmax/MIC ratio is more than 8-
10 and when AUC/MIC is > 100. Accordingly, to optimise efficacy with these agents during 
CRRT, it may be more useful to extend the dosing interval while maintaining a fixed dosage24. 
Accordingly, to optimise efficacy with these agents during CRRT, it may be more useful to extend 
the dosing interval while maintaining a fixed dosage24. 
If CRRT contributes significantly to the total body clearance of a drug, a supplemental dose, 
corresponding to the amount of drug removed by CRRT, should be administered, making from 
equation 5: 
D = DN (CLANUR + CLCRRT)/CLN    [7]11 
Where CLCRRT is the CRRT drug clearance. 
Clearance by CRRT can be measured and is : 
CLCRRT = QE x CE/CP   [8]11 
Where, CE and CP are drug concentrations in effluent fluid and plasma, respectively. QE  is the 
effluent flow rate which is the sum of ultrafiltration flow rate (QUF) and dialysate flow rate (QD). 
Substitution into the above equation makes: 
D = DN (CLANUR + QE x CE/CP)/CLN     [9]11 
For most drugs, measurements are not available, and CRRT clearances have to be estimated. The 
sieving coefficient (SC) of a drug is the concentration in ultrafiltrate (CUF) divided by the 
concentration in plasma, making: 
SC= CUF/CP  [10]11,39,40 
The exact formula for the sieving coefficient is SC=2CUF/ (CPin + CPout), but the differences 
between CPin and CPout are negligible, making the above equation almost correct.  
Of note, drug protein binding is the main determinant of SC and it has been suggested that SC can 
be estimated from published values of protein binding, such that SC= 1 - PPB40,41. Measured SC 
and SC estimated from published values of PPB are correlated. However, as discussed below, PPB 
in the critically ill is variable and for some drugs SC varies widely (e.g. levofloxacin). 
Furthermore, SC may be affected by membrane material, drug-membrane interaction, and flux 
proprieties. Finally, for readily filterable molecules CUF approximates the concentration of 
unbound drug in plasma, and Sc can be estimated by the unbound fraction (fu) of the drug, making: 
CLCRRT = fu x QUF    or   CLCRRT = fu x (QUF + QD) [11]11 
 During CVVH or CVVHDF, respectively. The value of fu is retrieved from pharmacological tables, 
but as outlined above, the unbound fraction in the critically ill may differ from these values. CRRT 
performed in different mode (e.g. a pre-dilution/post-dilution) mode) are explained item by item in 
the 4th and 5th paragraphs. 
 
4. PRINCIPLES OF DRUG REMOVAL DURING RENAL REPLACEMENT THERAPIES 
: TECHNICAL FACTORS SPECIFIC TO EXTRACORPOREAL BLOOD 
PURIFICATION THERAPY  
 
4.1. Membrane 
Drug clearance is directly proportional to the surface area of the dialytic membrane or haemofilter, 
which usually is in the range of 0.5 to 2.0 m2. The pore size of the filter is the other crucial factor 
determining the extent of drug removal: the cut-off of the modern synthetic dialysis membranes 
(called high-flux dialytic membranes)is significant larger than that of the old cellulose or 
cuprophane membranes (< 1000 D).The modern membranes usually are made up of bio-synthetic 
material. (polysulfone, polyacrylonitrile, polyamide) with relatively larger pore sizes (5000 to 
20,000 D).  This means that high MW may protect some large molecules (e.g. glycopeptides) from 
removal when using old cuprophane membranes, whilst this does not occur when using high-flux 
dialytic membranes. Conversely, drug removal by haemofiltration doesn’t depend on molecule size, 
considering that all antimicrobial agents have MW lower than the haemofilter’s cut-off (20,000 to 
50,000 D). 
 
4.2. Diffusion (Haemodialysis) 
The efficiency of solute removal based on diffusion in haemodialysis is determined by the 
concentration gradient, in addition to the porosity and surface area of the dialytic membrane. 
Compared with convective clearance, diffusive clearance will decrease as MW increases. Owing to 
the lower diffusive permeability, greater influence of MW on diffusive clearance is found with 
conventional dialysis membranes than with the synthetic membranes used in CRRT. Diffusive 
clearance varies between the filter membranes and are greater for polyacrylonitrile (PAN, AN-69) 
than for polyamide.42 
In CVVHD, the counter-current flow of dialysate is always considerably smaller than blood flow, 
resulting in complete equilibration between blood plasma and dialysate. Therefore, the dialysate 
leaving the filter will be 100% saturated with at least the small, easily diffusible, solutes. Diffusive 
clearance of small unbound solutes will equal to QD. Dialysate saturation (Sd) represents the 
capacity of a drug to diffuse through a dialysis membrane and saturate the dialysate and is 
calculated by dividing drug concentration in the dialysate (Cd) by its plasma concentration (Cp): 
Sd = Cd/Cp [12]35,39,40 
Consequently, diffusive drug clearance (CLHD) is calculated by multiplying QD by Sd: 
CLHD = QD x Sd [13]35,39,40 
Because either a higher molecular weight decreases the speed of diffusion or a higher QD decreases 
the time available for diffusion, an increase in each of them will give rise to a decrease in Sd. 
 Sd can theoretically be influenced by drug-membrane interactions and by protein adsorption to the 
membrane. When extracorporeal drug clearance is calculated, Sd can be approximately replaced by 
the unbound fraction. Of note, however, Sd does not remain constant, and a serious error would 
result if the same Sd were used in different QD flows
39. 
 
4.3. Convection (Hemofiltration) 
Convective solute removal used in hemofiltration is not affected by MW up to the sieving cut off 
value of the membrane. Continuous hemofiltration usually uses highly permeable membranes, with 
high cut off values (20,000 to 50,000 D). Because most drugs fall in the lower- to middle-
molecular-size category, molecular weight will have little impact on drug sieving with 
haemofiltration. The capacity of a drug to pass through the membrane of a haemofilter is expressed 
mathematically in the SC term, which is the relation between drug concentration in the ultrafiltrate 
(Cuf) and in plasma (Cp). 
SC = Cuf/Cp [10]11 
For most antimicrobials, SC can be estimated by the extent of the unbound fraction (SC ≈ fu). 
Moreover, an excellent correlation was found between SC and the unbound fraction. SC is a 
dynamic parameter, however, and is dependent on the age of the membrane and the filtration 
fraction (QUF/QB, where QB is the blood flow rate). A loss of SC will be approximately 20% for 
drugs such as vancomycin after use of the membrane over 12 hours. Given a QB of 100 mL/minute, 
an increase in QUF from 14 mL/minute to 28 mL/minute will decrease the SC for drugs like 
vancomycin by approximately 30%. 
There are two basic dilution modes (pre and post dilution) for the substitution fluid, which may 
influence the solute removal efficiency. In the post dilution mode, the convective clearance of an 
antimicrobial agent (CLpost-HF) can thus be easily obtained by multiplying QUF by its SC: 
CLpost-HF = QUF X SC [14]35,39,43 
If haemofiltration is used in pre dilution mode, however, the drug concentration in the plasma 
entering the haemofilter is diluted by replacement fluid, so the drug clearance will be lowered by a 
correction factor (CF) determined by blood flow rate (QB) and pre dilution replacement rate (Qrep). 
Drug clearance in pre dilution mode can be calculated: 
CLpre-HF = QUF X SC X CF [15] 35,39 
Where CF = QB / (QB+ Qrep)
35. 
Thus, the point of dilution is only likely to significantly affect clearance if the rate of fluid 
replacement is high. This may partially explain the discrepancy between an in vitro study that failed 
to demonstrate a clinically significant effect of point of dilution35 and an in vivo study that revealed 
a clinically significant reduction in clearance during pre dilution CVVH. In addition, the ratio of pre 
dilution: post dilution influences SC as well as clearance. For vancomycin, SC steadily decreased as 
the proportion of pre-dilution decreased. It is evident from the above equations that clearance by 
CVVH is proportional to the ultrafiltration rate, and therefore dosing needs to be altered with 
changes in the ultrafiltration rate35,44. As the expected magnitude of change in ultrafiltration is 
substantially greater than the variability of SC, ultrafiltration is the more important consideration. 
 
4.4. Combination with Diffusion and Convection (Haemodiafiltration) 
In haemodiafiltration, solutes are removed by both diffusion and convection. The calculation of 
drug clearance during this combination therapy is extremely difficult, especially at different QUF 
and QD rates. Drug clearance with CVVHDF (CLHDF) in the post dilution phase may be estimated 
by calculating the convective clearance and diffusive clearance from the following equation: 
CLHDF = QUF X  SC + QD X Sd [16]35 
Greater overestimation will result if Sd is replaced by the unbound fraction. It was measured the 
extracorporeal clearance of several antimicrobials during continuous haemodiafiltration with a QUF 
of 400 mL/hour and a QD of 1 and 2 L/hour.
45 Compared with the calculated clearances based on 
the unbound fraction reported in healthy volunteers, the results show that the difference between 
calculated and measured clearance rates is not clinically significant with a low QD, but with a high 
QD, the calculated clearance may be overestimated by up to 100%. 
Because an interaction between diffusive and convective solute transfer has been demonstrated in 
intermittent high-flux haemodiafiltration by protein layer formation on the blood side of the 
capillary, it also gives the possibility for the two processes to interact in such a manner in CVVHDF 
that solute removal is significantly less than what would be expected if the individual components 
were simply added together. In CVVHDF, as the presence of convection-derived solute in the 
dialysate decreases the concentration gradient, the driving force for diffusion, the Sd, can be 
lowered even further. The diffusive clearance of a drug during CVVHDF is difficult to predict and 
will depend on its MW, QB, QD, and QUF and the membrane used. 
In order to not overestimate the CLHDF, recently Choi et al. proposed: 
CLHDF = (QUF  + QD) X Sd [17]35 
 
 
4.5. Adsorption to Membrane 
Adsorption to filter membranes leads to increased drug removal from plasma and the various filters 
have different adsorptive capacities. Some membranes such as polyacrylonitrile (PAN) may adsorb 
a substantial amount of drugs to their surface28. For example, Kronfol and Tian et al. found that 
PAN membranes have a high adsorbent capacity to bind aminoglycosides and levofloxacin. 
Adsorption is a saturant process, however, so the influence on drug removal will depend on the fre-
quency of filter changes45. In general, with filters lasting approximately 18–24 h, adsorption 
probably has a minor influence on drug removal, but at present, information about the various 
filters’ adsorptive capacity for most drugs is lacking. Filter adsorption is not accounted for in drug 
dosing guidelines5. Adsorption of drugs onto the membrane may lead to a reduction in membrane 
permeability and filtration rate over time5. Although dosing adjustment will not account for 
adsorption effects, using drug-adsorbing membranes for CRRT is usually not recommended. 
This phenomenon is more relevant in extracorporeal therapy based on adsorbent cartridges. These 
treatments are utilised in different yields where the accumulation of toxic molecules could worsen 
the clinical conditions (septic shock) or to make up for a failed organ (liver failure). Unfortunately, 
even if in vitro data cast light on this problem, there is little and only preliminary data. 
Page et al. demonstrated in Coupled Plasma Filtration and Adsorption (CPFA) that the polystyrene 
cartridge may adsorb vancomycin and piperacillin with an effect that limits itself over time46.  
 
4.6. High volume-High filtration 
High-volume CRRT (HV-CRRT), such as HVHF, is increasingly used in septic patients with ARF 
in the ICU. Nevertheless, the different effects on pharmacological characteristics of antimicrobial 
removal between HV-RRT and low-volume CRRT (LV-CRRT) have been understated. 
Pharmacokinetic experiments have found that many antimicrobials exhibit two and three 
compartment characteristics. The central compartment is often referred to as the plasma space, 
whereas the other compartments are peripheral compartments representative of various tissues in 
the body. In standard LV-CRRT, the rate-limiting step of drug clearance has been QD or QUF, 
because QB greatly exceeds QD or QUF . Consequently, no appreciable rebound occurs after LV-
CRRT stops because the drug transfers to the central compartment at least as fast as it is being 
removed by CRRT. At HV-CRRT initiation, the central compartment becomes rapidly stripped of 
unbound drug. The rate-limiting step for any further drug removal becomes the rate at which drug 
can transfer from the peripheral compartments into the central compartment for removal by HV-
RRT. As mentioned earlier, an increase in QUF from 14 mL/ minute to 28 mL/minute will decrease 
the SC for drugs like vancomycin by approximately 30%. However, as QD increased from 8.3 
mL/minute up to 33.3 mL/minute, a 30% decline in vancomycin Sd and an 8% decline in urea Sd 
were seen with use of AN69 hemodiafilters47. Available data indicates that doubling QD from 
standard low-volume flows to higher dialysate flows may result in substantially less than a doubling 
of solute dialytic clearance, particularly for larger solutes. Increasing QD (to greater than 2000 
mL/hour) should result in decreasing Sd, but the rate of Sd decline is filter-dependent47. 
Therefore, the drug clearance calculation during HV-CRRT is rather complex, and the changed SC 
and Sd should be further considered. 
In the IVOIRE study (High-volume versus standard-volume haemofiltration: a multicentre 
randomized controlled trial for septic shock patients with acute kidney injury) a total of 140 
critically ill patients with septic shock and AKI were randomized to either HVHF at 70 mL/kg/h or 
standard-volume haemofiltration (SVHF) at 35 mL/kg/h, for a 96-h period. In 45 patients all 
antibiotics were dosed during 5 days. All antibiotics were given at a standard dosage used in non-
AKI patients (i.e. 16 g per day for piperacillin or 2 g per day for ceftriaxone) and at the same dosage 
in the two groups to avoid bias as recommended by the external reviewers at study acceptance by 
the authorities. 
 All antibiotics were easily filtered, and mean sieving coefficients were from 38.70 to 96.70 %. The 
mean elimination half-life of all the agents in the HVHF group (from 1.29 to 28.54 h) was 
significantly shorter than that reported in the SVHF group (from 1.51 to 33.85 h)48. 
5. RATIONALE FOR APPROPRIATE DOSAGE ADJUSTEMENT OF ANTIBIOTICS 
DURING CRRT 
 
In patients with concomitant renal failure on CRRT, underdosing may lead to inadequate antibiotics 
therapy, with increased mortality risk, whereas overdosing may lead to drug accumulation and 
unnecessary toxicities. Drug dosing adjustments during CRRT can be guided by using available 
drugdosing recommendations, by measuring or estimating CRRT drug clearance, or by monitoring 
drug serum concentrations. Drug-dosing recommendations for patients with ARF receiving CRRT 
is always in progress with the advances in CRRT technology, the introduction of new 
extracorporeal therapies in septic shock or organ failure and the selling of new antimicrobial agents. 
Nonetheless, published drug-dosing recommendations for ARF patients on CRRT are becoming 
available but still limited. After searching the literature and reviewing recent clinical investigations, 
we adopted some of these recommendations. Then we summarized the pharmacokinetic 
characteristics and dosing recommendations of some antimicrobials most commonly used in 
critically ill patients undergoing CRRT into a complete dosing guide (Table 3). 
It is widely recognized that the extent of drug removal during CRRT in critically ill patients with 
ARF is dependent on numerous factors of patient, illness, drug, and the operational modality of 
CRRT. These parameters vary widely among different patients, or even during the length of stay in 
the same patient. 
CRRT does not always yield stable conditions, because QB and  QUF may vary ongoing. Moreover, 
the renal function and critical illness may reverse under effective treatment during the disease 
course. Therefore, it is extremely difficult and almost impossible to devise a comprehensive dosing 
guide for various antimicrobials that encompasses all of the potentially changing variables involved 
in CRRT for all patients, as well as for the various combinations of prescriptions, machines, filters, 
and other variables. Therapy must be individualized to the needs of each patient. 
Making these estimates is time-consuming, requiring a careful search for basic pharmacokinetic 
data. 
Based on the understanding of the principles of drug removal by CRRT and the pharmacokinetics of 
various antimicrobial agents, the drug dosage and dosing interval may be estimated using 
mathematical equations for application in individualized therapy. Drug clearance must be calculated 
to determine a maintenance dose. The serum concentration at steady state (Cpss) multiplied by the 
CLEC provides the clinician with the amount of drug specifically removed by ultrafiltration per hour 
under steady-state conditions28. Therefore, the amount of drug removed by CRRT (DEC) can be 
calculated using the following equation: 
DEC = Cpss xCLEC X Tdur[18]28 
where Tdur is the duration of CRRT. 
CLEC can be calculated using Equations 11, 12 to 13, and 14, as shown previously, according to 
treatment modality. The total amount of drug required during CRRT (D) may be calculated using 
the following equation, including the typical anuric dose (Danur) in addition to DEC: 
D = Danur + DEC = Danur + Cpss x CLEC xTdur[19]28 
Besides Equation 17, the drug dose during CRRT in an anuric patient also may be estimated using 
the following equation45: 
D = Danur x [1 + CLEC/CLNR/2(interval/half-life)] [20] 
where“half-life” is the T1/2 of the drug in an anuric non-dialyzed patient and “interval” is the dose 
 
interval in an anuric non-dialyzed patient. 
At present, there is an increasing tendency to start CRRT earlier in the course of illness, and RRT 
may contribute to drug clearance. According to Dettli's equation and the related investigation by 
Keller and associates, the estimated dose during CRRT in a patient with RRT may be calculated as 
follows45: 
DEC = Dn x [Px + (1 - Px) X CLCRtot/CLCRn] [21] 
Where Dn is the normal dose, Px = CLNR/CLN (in which CLN = normal drug clearance), CLCRtot is 
the sum of renal and extracorporeal creatinine clearance, and CLCRn is the normal creatinine 
clearance. This equation uses the patient's actual creatinine clearance to estimate drug clearance and 
drug dosing, and dose estimates will automatically be adjusted as changes occur in renal function45. 
Although complex mathematical models have been proposed, an accurate and usable equation 
remains unavailable. Most mathematical models are demonstrated to be suitable for use only with 
certain drugs on a conditional basis; their application in clinical practice is still limited. 
In summary, four formulas are proposed on the basis of CRRT modality in following Table 4 35: 
 
1. Modality Formula 
2. CVVH 
3. DCVVH = Cpss x QUF x fux I 
4. DCVVH = DN x [(CLNR + (QUF x SC))/CLN] 
5. CVVHDF 6. DCVVHDF  =DN x [Px + (1 - Px) X CLCRtot/CLCRn] 
7. All modality 8. D = Danuria / [1- (CLEC/(CLEC + CLNR +  CLR))] 
Cpss, measured blood concentration at steady state;  CLCRn, normal creatinine clearance; CLCRtot, sum of renal 
and extracorporal creatinine clearance; CLECextracorporeal clearance; CLN, normal total drug clearance; 
CLNR, non renal clearance; CLRrenal clearance; Danuria, recommended dose for anuric patients; DN, dose 
recommended for patients with normal renal function; I, dosing interval; Pxextrarenal clearance fraction (CL 
anur/CLN); SC, sieving coefficient; fu, unbound fraction; QUF, ultrafiltration rate. 
 
Whether it may be more appropriate to increase the drug dose or to shorten the dosing interval in 
critically ill patients during CRRT is dependent on antimicrobial mechanisms of action and the kill 
characteristics of the various classes of antimicrobial agents. For concentration-dependent kill 
characteristic antimicrobial agents, it is better to increase the drug dose, because their antimicrobial 
effects correlate with the Cmax. For example, low doses of aminoglycosides used in anuric non-
dialyzed patients result in low Cmax with low bacterial killing efficiency, although the risk of toxic 
adverse effects also is low. A preferable approach, however, is to increase the single daily dose to 
achieve the higher Cmax in CRRT, although the minimum (trough) drug concentration (Cmin) is 
decreased by CRRT and the risk of side effects is considerably reduced. By contrast, for time-
dependent kill characteristic antimicrobial agents such as β-lactam antibiotics, it is better to shorten 
the drug dosing interval, because their antibiotic effects correlate with T > MIC. The shorter dosing 
interval during CRRT may be estimated from the following equation, and the individual dose 
remains unchanged from that used in anuric no-dialyzed patients45: 
IvEC = Ivanu x [CLNR/CLEC + CLNR)] [22] 
Where IvEC is the interval during CRRT and Ivanu is the interval in an anuric patient. Not only are 
pharmacokinetics and pharmacodynamics often less predictable in critically ill patients, but it also 
has not been consistently shown that convincing results may be obtained from current drug dosing 
recommendations or be estimated accurately using available mathematical equations. Therefore, 
serum drug concentration monitoring is highly recommended whenever possible, especially for 
those drugs with a narrow therapeutic range. Although the monitoring of total drug concentrations is 
considered a reasonable strategy to enhance optimal dosing and minimize toxic side effects, it is no 
readily available for all medications. The following equation often is used to estimate the required 
dose (Drequired) to achieve the desired peak concentration (Cmax) from the actual trough (or any) 
concentration (Cactual)
45: 
Drequired = (Cmax -Cactual) x Vd x Body weight [23] 
 
Among all antimicrobial agents, aminoglycosides and glycopeptides have been studied more than 
other classes due to their proved nephrotoxicity. Recently, the increasing incidence of Extended-
spectrum β-lactamases (ESBLs) or carbapenemase-producing Gram-negative bacteria strains such 
as emergent linezolid-resistance staphylococci and enterococci boosted to consider the PK/PD 
relationship to achieve TCT in other antimicrobial classes. Unfortunately, in this field the recent 
literature is controversial and confirms the absolute variability of critically ill patient in term of 
PK/PD profiles. In our point of view, TDM represents the best tool to achievement the TCT. 
Nevertheless, PK/PD modeling and simulation software allow to guide dosing strategy for 
antibiotics and   might be utilized where the TDM is not available. 
Although the authors tried to categorize antimicrobial agents, the reality is that nearly all drugs 
undergo a combination of major, minor, and co-dominant elimination pathways. The authors 
proposed the adjustment dosage during CRRT, without taking into account the difference in 
prescribed CRRT dose. Exclusively, the dosage difference related to CRRT modality are shown in 
the table. The choice was imposed because in the setting of CRRT too much variables highly affect 
the plasma antimicrobials concentration during CRRT. Effectively, the type of filter, modality and 
intensity of CRRT, pre-dilution or post-dilution modality, partial preserved renal clearance, the 
adsorption by the membranes, and the addiction of adsorption techniques (e.g. cartridge of 
polystyrene resins) affect the drug plasma levels during the patient’s exposure of the 
pharmacological treatment. Table 3 limits to suggest the dosage, but the physician should take into 
account every PK/PD relationship, the breakpoint of the bacteria and the CRRT dose with its 
changes over time (e.g. decreasing of SC over time, delivery dose, and downtime).  
Drugbank, Micromedex, Sanford guide, Lexi-Comp, Epocrates, and other online or mobile 
databases offer extensively referenced continuously updated and easily available data on an 
extensive library of drugs31. A quick look at the pharmacokinetic or ADME sections of a drug 
monograph can help the practitioner quickly decide if renal dose adjustment is necessary. Highly 
similar drugs in the same class cannot be assumed to share common pharmacokinetics and 
elimination31. 
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 Figure 1. Plasma drug concentration-time profile and pharmacokinetic/pharmacodynamics 
relationship of antibiotics. 
Legend. T>MIC: the time for which a drug’s plasma concentration remains above the minimum 
inhibitory concentration (MIC) for a dosing period; Cmax/MIC: the ratio of the maximum plasma 
antibiotic concentration (Cmax) to MIC; AUC/MIC: the ratio of the area under the concentration-
time curve during a 24-hour time period (AUC) to MIC 
 
Figure 2. The interrelationship of hydrophilicity and lipophilicity of antibiotic molecules on the 
pharmacokinetic characteristics and the changes in critically ill patients. 
Legend. CL: clearance; Vd: volume of distribution. 
 
 
 
 
 
 
 
 
 
 Table 1. Mechanism of Action of Antimicrobial Agent 
Antimicrobial Agent 
Classes 
Mechanism of Action 
Aminoglycoside Agents 
Aminoglycoside agents are irreversible inhibitors of protein synthesis. Inside the 
microorganism, they bind to specific 30S subunit ribosomal protein. 
Beta-Lactam Agentes 
(Penicillin, Cephalosporin, 
and Carbapenem) 
Beta-lactam are irreversible inhibitors of cell-wall synthesis. Their bacteriostatic 
effect is related to inhibition of essential enzymes (transpeptidases, 
carboxypeptidases) involved in peptidoglycan biosynthesis. 
Fluoroquinolone Agents 
 
Fluoroquinolone agents are inhibitors of bacterial DNA synthesis. They inhibit 
bacterial topoisomerase II (DNA gyrase) and topoisomerase IV. This inhibition 
prevents the relaxation of positively supercoiled DNA is required for normal 
transcription and replication. 
 
Glycopeptide Agents 
Glycopeptide agents are irreversible inhibitors of the bacterial cell-wall synthesis. 
They bind to acyl-D-alanyl-D-alanine of peptidoglycan. 
Lipoglycopeptide Agents 
Lipoglycopeptide agents have a multiple mechanism of action. They combined action 
on the cell wall synthesis and disruption of bacterial cell membrane barrier function. 
They bind to acyl-D-alanyl-D-alanine of peptidoglycan. In addition, they bind bacterial 
target called as lipid II present in the cell membrane. 
Macrolide Agents 
Macrolide agents are agents are irreversible inhibitors of protein synthesis. They bind 
50S subunit of bacterial ribosomes, so tRNA translocation remains blocked. 
Miscellaneous Agents  
Aztreonam 
Aztreonam agent is irreversible inhibitor of cell-wall synthesis. 
Its effect is related to inhibition of penicillin binding protein 3 (PBP3). By binding to 
PBP3, aztreonam agent inhibits the third and last stage of peptidoglycan synthesis. 
Chloramphenicol 
Chloramphenicol agent is irreversible inhibitors of protein synthesis. It binds 50S 
subunit of bacterial ribosomes, so it prevents protein chain elongation (the 
peptidyltransferase activity is blocked). 
Clindamycin 
Clindamycin agent is irreversible inhibitors of protein synthesis. It specifically binds 
the 23S RNA subunit of 50S bacterial ribosome subunit. 
Colistin 
Colistin agent is a surface active agent which penetrates into and disrupts the 
bacterial cell membrane. It is polycationic and has both hydrophobic and lipophilic 
moieties. It interacts with the bacterial cytoplasmic membrane, changing its 
permeability. In addition, inside the microorganism, Colistin causes the precipitation 
of cytoplasmic components, primarily ribosomes. 
 
Daptomycin 
Daptomycin agent interferes with activity of the bacterial cell membrane. The 
binding and integration of Daptomycin into the cell membrane is calcium dependent. 
It causes rapid depolarisation, resulting in a loss of membrane potential leading to 
inhibition of protein, DNA and RNA synthesis, which results in bacterial cell death. 
Fidaxomicin 
Fidaxomicin agent specifically inhibits nucleic acid synthesis by impairing the 
initiation of RNA chain synthesis and transcription. Its effect is related to inhibition of 
RNA polymerase activity, so the transcription process remains blocked. 
Metronidazole 
Metronidazole agent is a pro-drug which is converted inside anaerobic bacteria in its 
active form by oxredox reaction. The reduced form of  Metronidazole covalently 
binds to DNA, disrupt its helical structure, inhibiting bacterial nucleic acid synthesis. 
Trimethoprim 
Trimethoprim agent inhibits bacterial DNA synthesis. Trimethoprim binds to 
dihydrofolate reductase and inhibits the reduction of dihydrofolic acid to 
tetrahydrofolic acid (Trimethoprim's affinity for bacterial dihydrofolate reductase is 
several thousand times greater than its affinity for human dihydrofolate reductase). 
Oxazolidinone Agents 
Oxazolidinone agents are irreversible inhibitors of protein synthesis. They bind to a 
site on the bacterial 23S ribosomal RNA of the 50S subunit and prevent the formation 
of a functional 70S initiation complex. 
Tetracycline Agents 
Tetracycline agents inhibit bacterial protein synthesis by preventing the association 
of aminoacyl-tRNA with the 30S bacterial ribosome subunit. 
Antifungal Agents  
Azole 
Azole- based antifungal agents are irreversible inhibitors of ergosterol synthesis. They 
inhibit the 14-α-sterol-demethylase enzyme involved in ergosterol biosynthetic 
pathway. This inhibition leads to accumulation of 14-α-methylsterols on the fungal 
surface, which results in arrest of fungal growth. 
Antimetabolite (Flucytosine) 
 
Flucytosine agent acts directly on fungal organisms by competitive inhibition of 
purine and pyrimidine uptake and indirectly by intracellular metabolism to 5-
fluorouracil. Inside the fungal cell, Flucytosine is metabolized to 5-fluorouracil, which 
is extensively incorporated into RNA and inhibits synthesis of both DNA and RNA. It 
also appears to be an inhibitor of fungal thymidylate synthase. 
Echinocandin 
Echinocandine agents are inhibitors of fungal cell-wall. They inhibit beta-(1,3)-glucan 
synthase involved in the synthesis of beta-(1,3)-D-glucan, an essential component of 
the cell-wall. 
Polyene  (Amphotericin B) 
Amphotericin B acts by irreversibly binding to ergosterol in the cell membrane. This 
creates a transmembrane channel, and the resultant change in membrane 
permeability allowing leakage of intracellular components. 
Antituberculous Agents  
Ethambutol 
Ethambutol agent inhibits arabinosyl transferases which is involved in cell wall 
biosynthesis. By inhibiting this enzyme an increase in cell wall permeability occurs. 
Isoniazid 
Isoniazid agent pro-drug which has to be activated by bacterial catalase. 
The active form of Isoniazid inhibits the synthesis of mycoloic acids, an essential 
component of the bacterial cell wall. 
Rifampicin 
Rifampicin agent acts by inhibition of RNA synthesis. It binds and blocks DNA-
dependent RNA polymerase enzyme. 
 
Table 2.  Recommended dosing regimen of most frequently renally excreted antibiotics based on renal function (modified by Pea et al.)49 
Renal function 
Antibiotic 
Increased 
(hypoalbuminemia or increased CI) 
Normal 
Moderately 
impaired 
CLCr 10-50 ml/min 
Severely impaired 
CLCr < 10ml/min 
Piperacillin/tazobatam 
16/2 g q24h CI or 4/0.5 g q6h EI over 
4 hours 
4/0.5 g q6h 
(ClCr >40 ml/min) 
4/0.5 g q6h* 
(CLCr 20-40 ml/min) 
2/0.25 g q6h* 
(CLCr ≤ 20 ml/min) 
Ampicillin/sulbactam 3 gm q6h 3 3 gm q6h 3 gm q8-12h 3 gm q24h 
Cefotaxime 4 to 6 g q24h CI or 2 g q4-6h 2 g q6-8h 2 g q8-12h 1 g q6-8h 
Ceftazidime 4 to 6 g q24h CI 2 g q8h 1 g q8-12h 0.5 to 1 g q24h 
Cefepime 
4 to 6 g q24h CI  or 
2 g q8h EI over 
3 hours 
2 g q8h 
6g 24h CI 
(CLCr > 60 ml/min) 
2 g q12h 
or 4g 24 h CI 
(CLCr 30-60ml/min) 
2 g 24 h CI (if CLCr 10-30 
ml/min) 
1 g q24h 
Imipenem 
500 mg q4h or 
250 mg q3h over 
3 hours CI 
500 mg q6h 250 mg q6h 250 mg q12h 
Meropenem 
1 g q4-6h over 6 hours CI /EI 
 
1 g q6h EI 
1g q12h EI 
if CLCr 20-50 ml/min 
250 mg q12h EI 
If CLCr ≤ 20 ml/min 
Ertapenem 
LD 2g  
Increased frequency of administration (e.g. 1g 
q12h) 
1 g q24h 1 g q24h 500 mg q24h 
Gentamycin 9 to 10 mg/kg q24h 7 mg/kg q24h 7 mg/kg q36-48h 7 mg/kg q48-96h 
Tobramycin 9 to 10 mg/kg q24h 7 mg/kg q24h 7 mg/kg q36-48h 7 mg/kg q48-96h 
Amikacin 25 mg/kg q24h 20 mg/kg q24h 15 mg/kg q36-48h 15 mg/kg q48-96h 
Ciprofloxacin 
600 mg q12h or 
400 mg q8h 
   400 mg q12h 400 mg q12h 400 mg q24h 
Levofloxacin 500 mg q12h 750 mg q24h/500 mg q12h 
500 mg q24h 
If CLCr 20-49 ml/min 
500 mg q48h 
If CLCr ≤ 20 ml/min 
Vancomycin 
LD 30 mg/kg 
MD2-3g CI q24h CI 
LD 20 mg/kg 
2g CI 
1-1,5 g 24h CI 0,5 -1  g 24 CI 
Teicoplanin 
LD 12 mg/kg q12h for 
3 to 4 doses; MD 6 mg/kg  q12 
 
LD 12 mg/kg q12h for 3 to 4 doses; MD 
4 to 
6 mg/kg q12h 
LD 12 mg/kg q12h for 
3 to 4 doses; MD 2 to 
4 mg/kg q12h 
LD 12 mg/kg q12h for 
3 to 4 doses; MD 2 to 
4 mg/kg q24h 
Daptomycin 6-8 mg/kg q24h 6 mg/kg q24h 
6 mg/kg q24h 
If CLCr > 30 ml/min 
6 mg/kg q48h 
If CLCr ≤ 30 ml/min 
Metronidazole 500mg q6h 7mg/kg q6h 7mg/kg q6h 7mg/kg q12h 
Fluconazole 
LD 800mg first day 
MD 400 mg q24 
LD 800mg first day 
MD 400 mg q24 
LD 400mg first day 
MD 400 mg q24 
LD 200mg first day 
MD 200 mg q24 
 
 
 
 
 
Table 3. Adjustment of Antimicrobial Regimen for different Drugs in patients with Acute Renal Failure Undergoing Continuous Renal 
Replacement Therapy (CRRT) 
Antimicrobial Agent MW LogP 
PPB 
[%] 
Vd [L/Kg] T1/2 [h] 
T1/2 anuria 
(h) 
Standard Dosage 
Dosage Adjustment 
on CRRT 
Aminoglycoside Agents (Concentration-dependent) 
Amikacin 585.6 -3.2 0-11 0.13- 0.29 2- 3 4-82 20 mg/kg q24h 
LD 25 mg/kg MD 7.5/kg 
q24-48 h 
Gentamicin 477.6 -1.6 0-30 0.29- 0.37 2 50-70 7 mg/kg q24h 
LD 3mg/Kg MD 2mg/kg 
q24-48 
Netilmicin 475.6 -1.4 0-30 0.16- 0.34 1.99-3.2 32-52 2.0 mg/kg q8h 2.0 mg/kg q8h pea 
Tobramycin 467.5 -3.0 10 0.26-0.32 2 53 7 mg/kg q24h 
LD 3mg/Kg MD 2mg/kg 
q24-48 
Carbapenem Agents (time-dependent) 
Ertapenem 475.52 -0.20 95 0.12 4h 14h 1g q14h 
CVVHDF/CVVHD 1g 
q24h 
Imipenem 299.3 -0.19 20 0.14-0.23 1 3 0.5-1.0 g q6h 0.5 mg q6-8 h 
Meropenem 383.5 -0.69 2 0.25 1 3.4-20 
1.0 g q6hLD EI or 2g 
q6h 
CVVH/CVVHD/CVVHDF 0.5 
q6-8h up to 1g q4-6 h (residual 
CLR ) 
Cephalosporin Agents (time-dependent) 
1st Generation         
Cefazolin 454.5 -0.4 74-86 0.14 1.8 40-70 0.5-1.5 g q6-8h 
CVVH 1-2g q12h 
CVVHD or CVVHDF 2g 
q12h 
Cefradine 349.4 0.7 8-17 0.30 0.7-1.3 8-15 1.0g q6h 1g q12h 
Cephalexin 347.4 0.55 15-20 0.23-0.35 0.7-1 16 0.5-1 g q6h 0.5g q12h 
2nd Generation         
Cefaclor 367.8 0.85 25 0.24-0.35 0.5-1 2-3 250-500 mg q8h 500mg q8-12h 
Cefamandole 462.5 -0.05 56-78 0.16-0.25 1 11 0.5-1.0 g q4-8h 1g q18h 
Cefoxitin 427.4 0.22 41-75 0.12-0.20 1 13-23 1.0-2.0 g q6-8h 1g q18h 
Cefuroxime 424.4 -0.24 50 0.25-0.30 1.4-1.8 17-20 0.75-1.5 g q8h  CVVH 0.5g q8h  
3rd Generation         
Cefmenoxime 511.6 -0.13 77-84 0.10-0.35 0.78-1.6 15.6 1.0 g q6h CVVH Quf 1L/h 1g q24h 
Cefoperazone 645.7 -0.11 82-93 0.14-0.20 2.4 2.4 1.0-2.0 g q12h 1-2 g q24h 
Cefotaxime 455.5 0.14 27-38 0.25-0.35 0.8-1.4 10-15 2.0 g q6-8h CVVH 1g q6h 
Ceftazidime 546.6 -1.2 5-17 0.28-0.36 1.9 21-23 1.0-2.0 g q8h 
1g q8h  or 3g/day IC    up 
to 2g q8h  
3g q8h for 
intermediatelyresistent 
patogenswith MIC8mg/ml  
Ceftriaxone 554.6 -0.01 95 0.08-0.3 5.8-8.7 8-16 2 g q12h or 2g q24h 2 g q24h or 2g q 12 h 
4th Generation         
Cefepime 480.6 -0.37 16-20 0.33-0.40 2 13.5 
2 g q8h 
6g 24h CI 
 
1-2 g q12h 
2g q8h (residual CLR) 
Cefpirome 514.6 -1.01 10 0.32 1.4-2.3 14.5 2.0 g q12h 
1g q12h (werf) 
2g q8h 
 
Antimicrobial Agent MW LogP PPB [%] 
Vd 
[L/Kg] 
T1/2 (h) 
T1/2anuria 
(h) 
Standard Dosage 
Dosage Adjustment 
on CRRT 
Fluoroquinolone Agents (concentration-dependent with PAE) 
Ciprofloxacin 331.3 -0.57 20-40 1.2-2.7 3-6 8.7 400 mg q6h 400mg q12-24h 
Enoxacin 320.3 -0.97 40 2 4-6 30 200-400 mg q12h 400mg q24h 
Levofloxacin 361.4 -0.02 24-38 1.25 6-8 40 
750 mg q24h 
500mg q12h 
LD 0.5 mg/die 
MD 0.25 g q24h or 0.5 g 
q48h 
0.5 g q24h residual CLR  or 
QUF  > 3 L/h 
Moxifloxacin 401.4 0.01 30-50 1.7-2.7 11.5-15.6 12 400 mg q24h 400 mg q24h 
Ofloxacin 361.4 -0.02 20-32 2.4-3.5 5-10 40 400 mg q12h 400mg q8h 
Pefloxacin 333.4 0.2 20-30 1.5-1.9 7-14 8.5-15 400 mg q12h 400-800mg q24h 
Glycopeptide Agents (time-dependent with PAE) 
Teicoplanin 
1877,7-
1879.7-
1893.7 
1.74 >90 0.9-1.6 88-140 157-567 
LD 12 mg/kg q12h for 
3 to 4 doses; MD 4 to 
6 mg/kg q12h 
LD 6mg/kg q12 for 3-4 
doses, MD 3-6 mg/kg q24 
Vancomycin 1449.2 1.11 55 0.7 4-6 180 2g CI 
LD 15-20 mg/kg   mg/kg 
MD 0.5 q12h 
H-HF 1g q12h  
Ramoplanin 2554.1 1.7 
minimal 
systemic 
absorption 
following oral 
administration 
minimal 
systemic 
absorption 
following 
oral 
administrati
on 
3.8 ND 200-400 mg q12h NA 
Lipoglycopeptide Agents (time-dependent, concentration-enhanced, with PAE) 
Dalbavancin 1816.7 3.58 93-99 0.1-0.19 204-346 376 
Single dose 1500 mg/ 
1000 mg + 500 mg 1 
week later 
NA 
Oritavancin 1793.1 1.92 85 1.25 245 ND Single dose 1200 mg NA (vitro study) 
Telavancin 1792.1 2.32 90 0.14 7-9 ND 10 mg/kg q24h NA (vitro study) 
Macrolide Agents (time-dependent) 
Clarithromycin 748.0 3.18 50-70 3 3-7 4 500 mg q12h 500mg q12h 
Erythromycin 733.9 2.37 75-95 0.75 0.8-3 5.4 
250-500 mg every 6 
hours 
NA 
Azitromicina       500mg q24h 500mg q24h 
Miscellaneous Agents 
Aztreonam 435.4 0.04 56 0.1-0.2 1.6-2.9 8.4 1.0-2.0 g q8-12h 
CVVH 1.0-2.0 g q12h 
CVVHDF CVVHD 2g q12 
Chloramphenicol 323.1 1.15 50-60 0.5-1 1.6-3.3 3-7 12.5-25 mg/kg q6h NA 
Clindamycin 425.0 1.76 60-95 0.6-1.2 2.4 4 600 mg q6-8h 600mg q6-8h 
Colistin 1634.9 -1.23 50 0.34 9 13 
LD 9 million U 
MD 4.5 million U 
q12h 
 CVVH LD 9 million U 
MD 4.5 million U q12h 
 CVVHDF LD 12 million 
U 6.5-7.5 million U q12h 
Daptomycin 1620.7 -0.47 90-93 0.1 8 30 4-6 mg/kg q24h 4-6mg/Kg q48h 
Fidaxomicin 1058.0 5.59 
minimal 
systemic 
absorption 
following oral 
administration 
minimal 
systemic 
absorption 
following 
oral 
administrati
on 
11.7 ND 200 mg q12h NA 
Metronidazole 171.1 -0.15 <20 0.55 6-14 7-21 7.5 mg/kg q6h 7.5 mg q6h 
Trimethoprim 290.3 1.26 42-46 0.7-1.5 8-11 24-30 100-200 mg q12h 100-200mg q12h 
Trimethoprim/ 
(Sulfamethoxazole 
1:5) 
290.3 
(253.3) 
1.26 
(0.79) 
42-46 
(70) 
0.7-1.5 
(0.3) 
8-11 
(10) 
24-30 
(80) 
2.5–5 mg/kg q6h. (NA) 
Penicillin Agents (time-dependent) 
Amoxicillin 365.4 0.75 20 0.26-0.31 1 5-20 500 mg q8h NA 
Ampicillin/ 
(Sulbactam 2:1) 
349.4 0.88 20 0.38 1-1.9 15-20 3g q8h 
CVVH 3g q12h 
CVVHD or CVVHDF 3g 
q8h 
Azlocillin 461.5 0.2 30-46 0.21 1.3-1.5 5-6 3.0 g q4h/4.0 g q6h 3g q24h  
 
Antimicrobial Agent MW LogP PPB Vd [L/Kg] T1/2 (h) 
T1/2anuria 
(h) 
Standard Dosage 
Dosage Adjustment 
on CRRT 
Flucloxacillin 453.9 2.69 95 0.14 0.75-1.5 2.3-2.8 2.0 g q4-6h 2g q6h or 1g q4h 
Mezlocillin 539.6 0.21 16-42 0.14-0.24 0.7-1.1 6 3.0 g q6h 2g q24h 
Nafcillin 414.5 3.21 90 0.24 0.5-1 4 2.0 g q4h 2g q4-6h 
Oxacillin 401.4 2.05 92-96 0.2 0.5 1 4.0 g q4-6h 2g q4-6h 
Penicillin G 334.4 1.92 65 0.2-0.7 0.5-1 5 0.8-4.0 millionU q4-6h 2 million U q12h 
Piperacillin/ 
(Tazobactam 8:1) 
517.6 0.65 16 0.18-0.3 1 5-6 4.5 g q6h 
4,0g/0.5g q6-8h  Depends 
on partial CLR preserved 
and in setting at high risk of 
pathogens with borderline 
susceptibility (MIC 32-64 
mg/ml) 
Ticarcillin/ 
(Clavulanate 30:1) 
384.4 0.99 45-65 0.21 1.1 13 3.1 g q6h 
CVVH 2g q6-8h 
CVVHD or CVVHDF 3.1 g 
q6h 
Oxazolidinone Agents (time-dependent) 
Linezolid 337.3 0.61 31 0.64 4.7 5.4 600 mg q12h 
600 mg q12h 
HV-HF  600mg q8 h the 
non –CRRT related 
clearance represents the 
most factor in interpatient 
variability 
Tedizolid 450.3 0.82 70-90 1-1.14 11 11 200 mg q24h In vitro study 
Tetracycline Agents (time-dependent, concentration-enhanced, with PAE) 
Doxycycline 444.4 -0.72 80-93 0.75 15-24 18-25 100-200 mg q24h 100mg q24h 
Tigecycline 585.6 0.66 71-89 7-9 42 42 50 mg q12h 50-100mg q12h 
Antifungal Agents 
Azole 
Fluconazole 306.3 0.58 12 0.7 27 100 400-800 mg q24h 
0.8 g  q24h CVVH with 
QUF up to 2L/h or 0.4-0.6 g 
q 12h CVVHDF 
Itraconazole, IV 705.6 5.48 99.8 10 21 35 200 mg q12h or q24h 100-200mg q 12h 
Posaconazole 700.8 4.71 98.2 5-25 35 35 200-400 mg q12h NA 
Voriconazole, IV 349.3 1.65 58 4.6 12 13.7 
6 mg/kg q12h twice, 
then 4 mg/kg q12h 
6 mg/kg q12h twice, then 4 
mg/kg q12h* 
Antimetabolite 
Flucytosine 129.1 -0.24 4 0.6-0.9 4 85 25-37.5 mg/kg q6h 25-37.5 mg/kg q6h 
Echinocandine 
Caspofungin 1093.3 0.17 97 9.67 9-11 13 
70 mg once, then 50 
mg q24h 
70 mg once, then 50 mg 
q24h 
Anidulafungina 1140.2 1.87 >99 0.6 40-50 40-50 
LD 200mg first day 
MD 100mg q24h 
CVVHDF LD 200mg first 
day 
MD 100mg q24h 
Micafungin 1270.3 0.67 >99 0.39 10-15 10-15 100-150 mg q24h  
Polyene 
Amphotericin B 
Lipid formulations 
(lipix complex 
AMPB-LC or 
liposomial L- AMPB) 
924.1 -0.66 >90 4 173 173 5 mg/kg q24h 3-5 mg/kg q24h 
Antituberculous Agents 
Ethambutol 204.3 -0.12 20-30 1.6-3.89 2.5-4 7-15 15-25 mg/kg q24h 15-25 mg/kg q24h 
Isoniazid 137.1 -0.71 15 0.57-0.76 0.7-4 8-17 300 mg q24h 300 mg q24h 
Rifampicin 822.9 3.85 89 0.93 3.5 11 600 mg q24h 600 mg q24h 
 
logP predicted values were calculated by ALOGPS  
*Itraconazole and voriconazole are available in oral and parenteral formulations. The parenteral formulations are solubilized in a cyclodextrin diluent, which is 
eliminated by the kidneys and will accumulate in patients with renal insufficiency. The clinical significance of cyclodextrin accumulation in humans is not fully 
understood5. 
 
